'Grand Slam' in Pancreatic Cancer: Novel Pill Doubles Survival

(MedPage Today) -- CHICAGO -- RASolute 302 trial results were hailed as a game-changing breakthrough in the treatment of pancreatic cancer. The phase III study showed that second-line daraxonrasib, an investigational oral RAS(ON) multi-selective...

Source

MedPage Today

Read full article at MedPage Today

Opens original article in a new tab

STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.

about 4 hours agoRead more →

Stat News

STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug

Much-awaited results at ASCO show that scientists have indeed found a way to drug a "greasy ball" involved in pancreatic cancer.

about 4 hours agoRead more →

Stat News

STAT+: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds

By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results were encouraging.

about 4 hours agoRead more →

Stat News

STAT+: BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA

ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.

about 18 hours agoRead more →

Related Health Stories

STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug

STAT+: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds

STAT+: BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA